Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study

Edward Wai Wa CHAN; Miriam Tim Yin LEUNG; Lauren Ka Wun LAU; Janice LEUNG; Dawn LUM; Rosa Sze Man WONG; Xue LI; Celine Sze Ling CHUI; Eric Yuk Fai WAN; Carlos King Ho WONG; Esther Wai Yin CHAN; Patrick IP; Ian Chi Kei WONG; Francisco Tsz Tsun LAI

doi:10.1016/j.ijid.2021.12.354

Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study

Edward Wai Wa CHAN
, Miriam Tim Yin LEUNG
, Lauren Ka Wun LAU
, Janice LEUNG
, Dawn LUM
, Rosa Sze Man WONG
, Xue LI
, Celine Sze Ling CHUI
, Eric Yuk Fai WAN
, Carlos King Ho WONG
, Esther Wai Yin CHAN
, Patrick IP
, Ian Chi Kei WONG
, Francisco Tsz Tsun LAI

Department of Special Education and Counselling (SEC)

Research output: Contribution to journal › Articles › peer-review

14 Citations (Scopus)

Abstract

Objectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant.

Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected.

Results: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk.

Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated. Copyright © 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

Original language	English
Pages (from-to)	47-50
Journal	International Journal of Infectious Diseases
Volume	116
Early online date	Dec 2021
DOIs	https://doi.org/10.1016/j.ijid.2021.12.354
Publication status	Published - Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Vaccine safety
Pharmacovigilance
Epidemiology
Pediatrics

Access to Document

10.1016/j.ijid.2021.12.354Licence: CC BY

Other files and links

CHAN, E. W. W., LEUNG, M. T. Y., LAU, L. K. W., LEUNG, J., LUM, D., WONG, R. S. M., LI, X., CHUI, C. S. L., WAN, E. Y. F., WONG, C. K. H., CHAN, E. W. Y., IP, P., WONG, I. C. K., & LAI, F. T. T. (2022). Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study. International Journal of Infectious Diseases, 116, 47-50. https://doi.org/10.1016/j.ijid.2021.12.354

Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study. / CHAN, Edward Wai Wa; LEUNG, Miriam Tim Yin; LAU, Lauren Ka Wun et al.
In: International Journal of Infectious Diseases, Vol. 116, 03.2022, p. 47-50.

Research output: Contribution to journal › Articles › peer-review

CHAN, EWW, LEUNG, MTY, LAU, LKW, LEUNG, J, LUM, D, WONG, RSM, LI, X, CHUI, CSL, WAN, EYF, WONG, CKH, CHAN, EWY, IP, P, WONG, ICK & LAI, FTT 2022, 'Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study', International Journal of Infectious Diseases, vol. 116, pp. 47-50. https://doi.org/10.1016/j.ijid.2021.12.354

@article{0ed0c32fdd004ed2a15dcaa4b81e39fb,

title = "Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study",

abstract = "Objectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. Results: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk. Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated. Copyright {\textcopyright} 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.",

author = "CHAN, \{Edward Wai Wa\} and LEUNG, \{Miriam Tim Yin\} and LAU, \{Lauren Ka Wun\} and Janice LEUNG and Dawn LUM and WONG, \{Rosa Sze Man\} and Xue LI and CHUI, \{Celine Sze Ling\} and WAN, \{Eric Yuk Fai\} and WONG, \{Carlos King Ho\} and CHAN, \{Esther Wai Yin\} and Patrick IP and WONG, \{Ian Chi Kei\} and LAI, \{Francisco Tsz Tsun\}",

year = "2022",

month = mar,

doi = "10.1016/j.ijid.2021.12.354",

language = "English",

volume = "116",

pages = "47--50",

journal = "International Journal of Infectious Diseases",

issn = "1201-9712",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study

AU - CHAN, Edward Wai Wa

AU - LEUNG, Miriam Tim Yin

AU - LAU, Lauren Ka Wun

AU - LEUNG, Janice

AU - LUM, Dawn

AU - WONG, Rosa Sze Man

AU - LI, Xue

AU - CHUI, Celine Sze Ling

AU - WAN, Eric Yuk Fai

AU - WONG, Carlos King Ho

AU - CHAN, Esther Wai Yin

AU - IP, Patrick

AU - WONG, Ian Chi Kei

AU - LAI, Francisco Tsz Tsun

PY - 2022/3

Y1 - 2022/3

N2 - Objectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. Results: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk. Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated. Copyright © 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

AB - Objectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. Results: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk. Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated. Copyright © 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

UR - https://www.scopus.com/pages/publications/85122672518

UR - https://doi.org/10.1016/j.ijid.2021.12.354

U2 - 10.1016/j.ijid.2021.12.354

DO - 10.1016/j.ijid.2021.12.354

M3 - Articles

C2 - 34965462

AN - SCOPUS:85122672518

SN - 1201-9712

VL - 116

SP - 47

EP - 50

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

ER -

Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: A prospective cohort study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint